Citations

Clear

6273 citation(s) found for "To, Andrew".

Binding of Pneumocystis carinii to the lung epithelial cell receptor HSPA5 (GRP78)
Hebrink, Deanne, Kottom, Theodore J. , Hebrink, Deanne M, Limper, Andrew H.

Mayo Clinic

Journal of Medical Microbiology | October 17, 2018 | Volume: 67 | Issue: 12 | Pages: 1772-1777

10.1099/jmm.0.000864 | PMID 30328808 Get It

Follicular Dendritic Cell Sarcoma With NF2 Mutation
Karrs, Jeremiah , Gohlke, Amanda Lynn, Oliveira, André M. , Richard, Hope , Pavlick, Dean C. , Smith, Steven C. , Poklepovic, Andrew

Mayo Clinic

AJSP: Reviews and Reports | October 16, 2018 | Volume: 23 | Issue: 6 | Pages: 251-254

10.1097/pcr.0000000000000277 Get It

Abstract Follicular dendritic cell sarcoma (FDCS) is recognized as a diagnostically challenging neoplasm requiring rigorous exclusion of more common entities and high index of suspicion for diagnosis. Here, we report an aggressive case of FDCS arising in the mediastinum, which due to sampling limitations and the inherent difficulty of diagnosis required extensive workup with multiple samples prior to definitive classification. The patient was a 35-year-old woman who presented with progressive dyspnea and mediastinal mass on imaging studies. The initial sampling of the lesion had histologic features raising consideration of FDCS, but was too limited to allow definitive diagnosis, while progressing rapidly enough to require administration of chemotherapy even prior to classification. Repeat samples obtained via fine-needle aspiration and bronchoscopy enabled the diagnosis of FDCS, and high-throughput sequencing revealed apparently pathogenic NF2 mutations previously not reported in this disease. Unfortunately, the patient died of widely metastatic disease, which we comprehensively documented at autopsy. Together, these observations provide previously unreported insights into the end stage of this disease and experience relevant to its prospective recognition and workup.
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
Veitch, Dallas P. , Weiner, Michael W. , Aisen, Paul, Cairns, Nigel J., Harvey, Danielle , Jack, Clifford R. , Jagust, William J. , Morris, John C. , Petersen, Ronald C. , Shaw, Leslie M. , Toga, Arthur W. , Trojanowski, John Q. , Initiative, Alzheimer's Disease Neuroimaging, Levey, Allan I. , Kantarci, Kejal , Fox, Nick C. , Mathis, Chester A. , Thompson, Paul M. , Donohue, Michael , DeCarli, Charles , Preda, Adrian , Carrillo, María C. , Turner, Raymond Scott , Bartha, Robert , Arfanakis, Konstantinos , Lamar, Melissa , DeCarli, Charles , Jack, Clifford R , Preda, Adrian , Toga, Arthur W , Thompson, Paul M , Kantarci, Kejal , Fox, Nick C , Morris, John C , Donohue, Michael C , Harvey, Danielle J , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Initiative, Alzheimer's Disease Neuroimaging, Levey, Allan I , Jimenez‐Maggiora, Gustavo Adolfo

Mayo Clinic

Alzheimer's & Dementia | October 13, 2018 | Volume: 15 | Issue: 1 | Pages: 106-152

10.1016/j.jalz.2018.08.005 | PMID 30321505 Get It

Abstract Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite, longitudinal, observational study that has collected many biomarkers since 2004. Recent publications highlight the multifactorial nature of late‐onset AD. We discuss selected topics that provide insights into AD progression and outline how this knowledge may improve clinical trials. Methods We used standard methods to identify nearly 600 publications using ADNI data from 2016 and 2017 (listed in Supplementary Material and searchable at http://adni.loni.usc.edu/news‐publications/publications/ ). Results (1) Data‐driven AD progression models supported multifactorial interactions rather than a linear cascade of events. (2) β‐Amyloid (Aβ) deposition occurred concurrently with functional connectivity changes within the default mode network in preclinical subjects and was followed by specific and progressive disconnection of functional and anatomical networks. (3) Changes in functional connectivity, volumetric measures, regional hypometabolism, and cognition were detectable at subthreshold levels of Aβ deposition. 4. Tau positron emission tomography imaging studies detailed a specific temporal and spatial pattern of tau pathology dependent on prior Aβ deposition, and related to subsequent cognitive decline. 5. Clustering studies using a wide range of modalities consistently identified a “typical AD” subgroup and a second subgroup characterized by executive impairment and widespread cortical atrophy in preclinical and prodromal subjects. 6. Vascular pathology burden may act through both Aβ dependent and independent mechanisms to exacerbate AD progression. 7. The APOE ε4 allele interacted with cerebrovascular disease to impede Aβ clearance mechanisms. 8. Genetic approaches identified novel genetic risk factors involving a wide range of processes, and demonstrated shared genetic risk for AD and vascular disorders, as well as the temporal and regional pathological associations of established AD risk alleles. 9. Knowledge of early pathological changes guided the development of novel prognostic biomarkers for preclinical subjects. 10. Placebo populations of randomized controlled clinical trials had highly variable trajectories of cognitive change, underscoring the importance of subject selection and monitoring. 11. Selection criteria based on Aβ positivity, hippocampal volume, baseline cognitive/functional measures, and APOE ε4 status in combination with improved cognitive outcome measures were projected to decrease clinical trial duration and cost. 12. Multiple concurrent therapies targeting vascular health and other AD pathology in addition to Aβ may be more effective than single therapies. Discussion ADNI publications from 2016 and 2017 supported the idea of AD as a multifactorial disease and provided insights into the complexities of AD disease progression. These findings guided the development of novel biomarkers and suggested that subject selection on the basis of multiple factors may lower AD clinical trial costs and duration. The use of multiple concurrent therapies in these trials may prove more effective in reversing AD disease progression.
Recurrent Genomic Alterations in Soft Tissue Perineuriomas
Carter, Jodi M. , Wu, Yanhong , Blessing, Melissa M. , Folpe, Andrew L. , Thorland, Erik C., Spinner, Robert J. , Jentoft, Mark E. , Baheti, Saurabh , Niu, Zhiyv , Mauermann, Michelle L. , Mauermann, Michelle L , Niu, Zhiyv , Wang, Chen , Klein, Christopher J. , Carter, Jodi

Mayo Clinic

American Journal of Surgical Pathology | October 10, 2018 | Volume: 42 | Issue: 12 | Pages: 1708-1714

10.1097/pas.0000000000001169 | PMID 30303818 Get It

Perineuriomas are rare nerve sheath tumors, divided into intraneural and extraneural (soft tissue) types. Intraneural perineuriomas frequently contain TRAF7 mutations, and rarely, chr22q12 deletions. While chr22q losses can occur in soft tissue perineuriomas, comprehensive high-resolution molecular profiling has not been reported in these tumors and TRAF7 status is unknown. We used whole-exome sequencing and OncoScan single nucleotide polymorphism (SNP) array to evaluate 14 soft tissue perineuriomas. Thirteen cases showed 2 or more chromosomal abnormalities, composed primarily of large deletions. Recurrent chr22q deletions, containing the NF2 locus (n=6) and the previously unreported finding of chr17q deletions, with the NF1 locus (n=4) were frequent events and were mutually exclusive in all but1 case. In addition, 5 cases had varying chr2 deletions; and 4 cases had chr6 deletions. A chr10 deletion (previously reported in the sclerosing variant of soft tissue perineurioma) was observed in one case and another case had chr7 chromothripsis as the sole chromosomal abnormality. No TRAF7 mutations or alterations were identified in any case and no other evaluated gene (MAF<0.0001) had recurrent, deleterious mutations in >2 cases. The molecular genetic profiles showed no association with patient sex, age, tumoral histology or anatomic site. OncoScan SNP array analysis was performed on 10 cases and showed high concordance with the whole exome data, validating the large-scale deletions, duplications, and chr7 chromothripsis findings. In soft tissue perineuriomas, recurrent 22q12 deletions (with NF2) and 17q11 deletions (with NF1) appear to be mutually exclusive events, and alterations in NF1 or NF2 likely contribute to perineurioma pathogenesis, similar to other nerve sheath tumors. Moreover, the lack of TRAF7 mutations in soft tissue perineuriomas indicates divergent pathogenetic mechanisms from those of intraneural perineuriomas.
Establishing a Core Outcome Measure for Life Participation: A Standardized Outcomes in Nephrology-kidney Transplantation Consensus Workshop Report
Ju, Angela , Jowsey‐Gregoire, Sheila G. , Tan, Jane C. , Taylor, Quinetta, Dobbels, Fabienne , Caskey, Fergus , Jha, Vivekanand , Locke, Jayme E. , Hanson, Camilla S., Sautenet, Bénédicte , Manera, Karine , Craig, Jonathan C. , Howell, Martin , Rutherford, Claudia , Tong, Allison , Watson, Christopher J.E. , Malone, Andrew F. , Jowsey-Gregoire, Sheila, Howell, Martin , Josephson, Michelle A. , Butt, Zeeshan A. , Fowler, Kevin John , Knoll, Greg A. , Ahn, Curie

Mayo Clinic

Transplantation | October 9, 2018 | Volume: 103 | Issue: 6 | Pages: 1199-1205

10.1097/tp.0000000000002476 | PMID 30300284 Get It

Background. Kidney transplantation confers substantial survival and quality of life benefits for many patients with end-stage kidney disease compared with dialysis, but complications and side effects of immunosuppression can impair participation in daily life activities. Life participation is a critically important patient-reported outcome for kidney transplant recipients but is infrequently and inconsistently measured in trials. We convened a consensus workshop on establishing an outcome measure for life participation for use in all trials in kidney transplantation. Methods. Twenty-five (43%) kidney transplant recipients/caregivers and 33 (57%) health professionals from 8 countries participated in 6 facilitated breakout group discussions. Transcripts were analyzed thematically. Results. Four themes were identified. Returning to normality conveyed the patients’ goals to fulfill their roles (ie, in their family, work, and community) and reestablish a normal lifestyle after transplant. Recognizing the diverse meaning and activities of “life” explicitly acknowledged life participation as a subjective concept that could refer to different activities (eg, employment, recreation, family duties) for each individual patient. Capturing vulnerability and fluctuations posttransplant (eg, due to complications and side-effects) distinguished between experiences in the first year posttransplant and the long-term impact of transplantation. Having a scientifically rigorous, feasible, and meaningful measure was expected to enable consistent and frequent assessment of life participation in trials in kidney transplantation. Conclusions. A feasible and validated core outcome measure for life participation is needed so that this critically important patient-reported outcome can be consistently and meaningfully assessed in trials in kidney transplantation to inform decision making and care of recipients.
Intensive Care Unit Readmission After Left Ventricular Assist Device Implantation: Causes, Associated Factors, and Association With Patient Mortality
Hui, John C.K., Mauermann, William J., Stulak, John M., Hanson, Andrew C. , Maltais, Simon, Barbara, David W.

Mayo Clinic

Anesthesia & Analgesia | October 9, 2018 | Volume: 128 | Issue: 6 | Pages: 1168-1174

10.1213/ane.0000000000003847 | PMID 31094784 Get It

BACKGROUND: Previous studies on readmissions after left ventricular assist device (LVAD) implantation have focused on hospital readmissions after dismissal from the index hospitalization. Because few data exist, the purpose of this study was to examine intensive care unit (ICU) readmissions in patients during their initial hospitalization for LVAD implantation to determine reasons for, factors associated with, and incidence of mortality after ICU readmission. METHODS: A retrospective analysis was performed from February 2007 to March 2015 of patients at our institution receiving first-time LVAD implantation. After LVAD implantation, patients dismissed from the ICU who then required ICU readmission before hospital dismissal were compared to those not requiring ICU readmission before hospital dismissal with respect to preoperative, intraoperative, and postoperative factors. RESULTS: Among 287 LVAD patients, 266 survived their initial ICU admission, of which 49 (18.4%) required ICU readmission. The most common reasons for readmission were bleeding and respiratory failure. Factors found to be univariably associated with ICU readmission were preoperative hemoglobin, preoperative aspartate aminotransferase, preoperative atrial fibrillation, preoperative dialysis, longer cardiopulmonary bypass times, and higher intraoperative allogeneic blood transfusion requirements. Multivariable analysis revealed ICU readmission to be independently associated with preoperative dialysis (odds ratio, 12.86; 95% confidence interval, 3.16–52.28; P < .001). Overall mortality at 1 year was 22.6%. Survival after hospital dismissal was worse for patients who required ICU readmission during the index hospitalization (adjusted hazard ratio, 2.35; 95% confidence interval, 1.15–4.81; P = .019). CONCLUSIONS: ICU readmission after LVAD implantation occurred relatively frequently and was significantly associated with 1-year mortality after hospital dismissal. These data can perhaps be used to identify subsets of LVAD patients at risk for ICU readmission and may lead to implementation of practice changes to mitigate ICU readmissions. Future larger and prospective studies are warranted.